Abstract：
Combination chemotherapy is the mainstay of treatment for acute lymphoblastic leukemia (ALL). The Hyper-CVAD regimen was developed in 1992 at MD Anderson Cancer Center and has since become a standard of care option for adult patients with ALL. Since its conception, a number of modifications have been implemented to customize the regimen for different patient populations and safely incorporate novel therapies without compromising tolerability. We aim to review the evolution of the Hyper-CVAD regimen over the past 3 decades, focusing on clinical pearls, as well as future directions.
摘要：
联合化疗是治疗急性淋巴细胞白血病（ALL）的主要手段。Hyper-CVAD方案于1992年在MDAnderson癌症中心开发，此后已成为成年ALL患者的标准护理选择。自从它的概念以来，已经实施了许多修改以针对不同患者群体定制治疗方案,并安全地纳入新疗法而不损害耐受性.我们的目标是回顾Hyper-CVAD方案在过去30年中的演变，专注于临床珍珠，以及未来的方向。
